TABLE 1

Patient Characteristics

Age (y)	Initial stage	Histology	CA-125 at treatment (kU/L)	²¹¹At treatment	Planned dosage (MBq in 1–2 L)
65	IIIC	Undifferentiated	<35	Yes	50
69	IIIA	LGSC	54	Yes	50
52	IIIC	HGSC	<35	Yes	50
43	IIIB	Endometrial	<35	Yes	100
47	IIA	Clear cell	<35	Yes	100
44	III	HGSC	<35	No^†
55	IIC	HGSC	<35	No^‡
38	IIIA	HGSC	<35^*	Yes	100
75	IIIB	HGSC	<35	No^§
44	IIIC	HGSC	<35	Yes	200
52	IIIC	HGSC	<35	Yes	200
59	IIIC	Undifferentiated	<35	No^ǁ
63	IIIA	HGSC	<35	No^§
52	IV	HGSC	<35	Yes	200
36	IIIC	HGSC	70	Yes	300
52	IIIB	HGSC	58	Yes	300
54	IIIC	Undifferentiated	<35	Yes	300

↵* Biopsy-proven residual disease on catheter procedure.
↵† No ²¹¹At treatment, because of perforation.
↵‡ No ²¹¹At treatment, because of poor distribution.
↵§ No ²¹¹At treatment, because of adherences.
↵ǁ No ²¹¹At treatment, because of abdominal carcinosis.
LGSC = low-grade serous ovarian cancer; HGSC = high-grade serous ovarian cancer.